


Accepted Manuscript

Title: Effect of non-cross-linked calcium on characteristics, swelling behaviour, drug release and mucoadhesiveness of calcium alginate beads

Author: Adnan Al Dalaty Ayman Karam Mohammad Najlah
Raid G. Alany Mouhamad Khoder



PII: S0144-8617(15)01188-1
DOI: <http://dx.doi.org/doi:10.1016/j.carbpol.2015.12.010>
Reference: CARP 10608

To appear in:

Received date: 7-10-2015
Revised date: 15-11-2015
Accepted date: 6-12-2015

Please cite this article as: Dalaty, A. A., Karam, A., Najlah, M., Alany, R. G., and Khoder, M., Effect of non-cross-linked calcium on characteristics, swelling behaviour, drug release and mucoadhesiveness of calcium alginate beads, *Carbohydrate Polymers* (2015), <http://dx.doi.org/10.1016/j.carbpol.2015.12.010>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **Effect of non-cross-linked calcium on characteristics, swelling behaviour, drug**
2 **release and mucoadhesiveness of calcium alginate beads**

3

4 Adnan Al Dalaty^a, Ayman Karam^b, Mohammad Najlah^c, Raid G. Alany^{d,e} and
5 Mouhamad Khoder^{a,d,*}

6 ^a University Al Baath, Faculty of Pharmacy, Homs, Syria

7 ^b Institut de Chimie des Milieux et Matériaux de Poitiers, CNRS, Université de
8 Poitiers/ENSIP, 1 rue Marcel Doré, 86073 Poitiers Cedex, France

9 ^c Faculty of Medical Science, Anglia Ruskin University, Bishops Hall Lane, Chelmsford
10 CM1 1SQ, United Kingdom

11 ^d School of Pharmacy and Chemistry, Faculty of Science, Engineering and Computing
12 Kingston University, London, Penrhyn Road, Kingston upon Thames, KT1 2EE Surrey,
13 United Kingdom.

14 ^e School of Pharmacy, The University of Auckland, Auckland, New Zealand

15

16 *Corresponding author

17 Mouhamad Khoder, Ph.D.

18 School of Pharmacy and Chemistry

19 Faculty of Science, Engineering and Computing

20 Kingston University London

21 Penrhyn Road, Kingston upon Thames,

22 KT1 2EE Surrey, UK.

23 e-mail: m.khoder@kingston.ac.uk

24

25

26 **ABSTRACT**

27 In this study, ibuprofen-loaded calcium alginate beads (CABs) with varying amounts of
28 non-cross-linked calcium (NCL-Ca) were prepared using different washing methods. The
29 influence of NCL-Ca on beads properties was investigated. Increasing the number or
30 duration of washes led to significant decreases in the amount of NCL-Ca whereas the
31 impact of the volume of washes was not significant. Approximately 70% of the initial
32 amount of Ca^{+2} was NCL-Ca which was removable by washing while only 30% was
33 cross-linked (CL-Ca). Ca^{+2} release from the CABs was bimodal; NCL-Ca was burst-
34 released followed by a slower release of CL-Ca. Washing methods and the amount of
35 NCL-Ca had significant influences on the encapsulation efficiency, beads weight, beads
36 swelling, drug release profile and the mucoadhesiveness of CABs. This study highlighted
37 the importance of washing methods and the amount of NCL-Ca to establish CABs
38 properties and understand their behaviour in the simulated intestinal fluids (SIFs).

39

40

41

42

43

44

45

46

47

48

49

50

51 **Keywords:** Calcium alginate beads, cross-linked calcium, non-cross-linked calcium,
52 encapsulation efficiency, mucoadhesiveness, drug release.

53

54 **1. Introduction**

55

56 Alginates are natural, nontoxic and biodegradable polysaccharide polymers available
57 in abundance from renewable sources (Tonnesen & Karlsen, 2002). Alginates form gel
58 under mild environment in the presence of divalent cations such as Zn^{+2} or Ca^{+2} without
59 the need for toxic reactants. Furthermore, alginates display very good muco- and
60 bioadhesive properties prolonging their residence time in different mucosal tissues
61 (Sosnik, 2014). Due to their unique properties and the gelation simplicity, alginates have
62 been widely used in many pharmaceutical applications such as the development of
63 mucoadhesive and controlled release delivery systems for drugs and proteins (Alipour,
64 Montaseri & Tafaghodi, 2010, Azarnia, Lee, Robert & Champagne, 2008, Barzegar-
65 Jalaliet al., 2013, Gray & Dowsett, 1988, Iskenderoglu, Acarturk, Erdogan & Bardakci,
66 2013, Jamstorp, Bodin, Gatenholm, Jeppsson & Stromme, 2010, Yanget al., 2013), the
67 immobilization/encapsulation of cells for tissue engineering applications (Singh, Deol &
68 Kaur, 2012, Xu, Xu, Wang, Ye, Zhou & Tan, 2014) and the bone regenerative medicine
69 (Despanget al., 2013, Schutz, Despang, Lode & Gelinsky, 2014).

70 Alginates are composed of 1–4 linked α -L-guluronic acid (G) and β -D-mannuronic acid
71 (M) arranged alternately in homopolymeric blocks (poly-M and poly-G) and in mixed
72 blocks (MG). The poly-G and the MG blocks are buckled while the poly-M blocks have a
73 shape referred to as an extended ribbon (Giri, Thakur, Alexander, Ajazuddin, Badwaik &
74 Tripathi, 2012, Sriamornsak, Thirawong & Korkerd, 2007). The cavities formed between
75 two adjacent guluronates in the poly-G or MG blocks are of dimensions that are ideal for
76 the cooperative binding of Ca^{+2} (George & Abraham, 2006). When a solution of sodium
77 alginate is extruded into a solution of calcium chloride, Ca^{+2} diffuses into the alginate
78 droplets. This causes the gelation of alginate and eventually the formation of CABs.
79 Whilst in the cavities among the guluronates, Ca^{+2} cross-link with poly-G and/or MG
80 blocks generating a gel with a characteristic structure known as an egg-box structure
81 (Donati, Holtan, Morch, Borgogna, Dentini & Skjak-Braek, 2005, Morch, Donati, Strand
82 & Skjak-Braek, 2006, Sriamornsak & Kennedy, 2008). Poly-M does not contribute to
83 cross-linking with divalent ions (Morch, Donati, Strand & Skjak-Braek, 2006). Thus, the
84 composition and block structure of alginates have an essential influence on both its
85 gelation and ion-binding properties (Morch, Donati, Strand & Skjak-Braek, 2006).

86 Rich in guluronate residues, CABs have a higher extent of cross-linking and a lower
87 release rate of encapsulated drug compared to that of fewer guluronate residues (Fathy,
88 Safwat, el-Shanawany, Shawky Tous & Otagiri, 1998, Sriamornsak & Kennedy, 2006).
89 The extent of alginate cross-linking is also influenced by the concentration of the cross-
90 linker solution and the curing time (Tateshita, Sugawara, Imai & Otagiri, 1993). In
91 general, the higher the concentration of Ca^{+2} solution and/or the longer the duration of
92 cross-linking process the greater is the extent of cross-linking, hence, slower drug release
93 (Heng, Chan & Wong, 2003, Rajinikanth, Sankar & Mishra, 2003). The composition of
94 the *in vitro* release testing medium may also have a significant effect on the rate of drug
95 release (Assifaoui, Chambin & Cayot, 2011). For example, release mediums containing
96 chelating agents such as phosphate salts or high concentration of monovalent ions
97 displace the cross-linkers, destabilize the beads and accelerate the drug release (Kim,
98 Chung, Shin, Yam & Chung, 2008).

99 The Ca^{+2} retained by CABs can be either CL-Ca which is tightly cross-linked with poly-
100 G and MG blocks or NCL-Ca having a weak interaction with the poly-M blocks
101 (Bourgeois, Gernet, Pradeau, Andremont & Fattal, 2006, Khoder, Tsapis, Huguet,
102 Besnard, Gueutin & Fattal, 2009, Kikuchi, Kawabuchi, Watanabe, Sugihara, Sakurai &
103 Okano, 1999). NCL-Ca is normally removable by a washing process whereas the CL-Ca
104 is not washable (Bourgeois, Gernet, Pradeau, Andremont & Fattal, 2006, Khoder, Tsapis,
105 Huguet, Besnard, Gueutin & Fattal, 2009). It is noteworthy that although the washing
106 methods are of great importance during the preparation of CABs, there have been very
107 little about it in literature. Furthermore, the influence of the NCL-Ca on the properties of
108 CABs and the rate of drug release has not yet been profoundly investigated. Similarly, the
109 influence of SIFs on the beads Ca^{+2} content and subsequently on the drug release profile
110 has not been adequately studied.

111

112 In this study, the preparation and characterisation of CABs containing different amount
113 of NCL-Ca are described. The impact of washing procedures on CABs properties is
114 investigated. And, to establish a validated method for drug release from CABs, beads
115 mucoadhesiveness, beads swelling behaviour and drug release profile are studied in two
116 different simulated intestinal fluids.

117

118 **2. Materials and methods**119 *2.1. Materials*

120 Sodium alginate extracted from *Laminaria hyperborea* with a MW of 1.97×10^5 and M/G
121 ratio of 0.59 was purchased from BDH Chemicals Limited, UK. Ibuprofen (IBU),
122 calcium chloride (CaCl_2), eriochrome black T and ethylenediaminetetraacetic acid
123 (EDTA) were supplied by Sigma-Aldrich, UK. Water was purified using automatic water
124 still (SAWS-1008 Shin saeng scientific co. ltd, Korea).

125 In order to investigate the impact of the composition of dissolution medium on the
126 swelling and drug release behaviours from CABs, two different simulated intestinal fluids
127 were freshly prepared as following:

128 a) Simulated intestinal fluid based on phosphate buffer (SIFp): contained 99.93
129 mmol KH_2PO_4 and 27.8 mmol NaOH. The pH was finally adjusted to 6.8 with
130 NaOH 1 M.

131 b) Simulated intestinal fluid based on maleate buffer (SIFm): 19.01 mmol Maleic
132 acid, 34.8 mmol NaOH and 68.69 mmol NaCl. The pH was adjusted to 6.8 with
133 NaOH 1 M.

134 *2.2. Preparation of CABs*

135 CABs loaded with IBU were prepared by ionotropic gelation using CaCl_2 as a cross-
136 linker. Briefly, 3 g of SA was dissolved in 100 mL of deionized water and 2 g of IBU
137 were added to the alginate solution and thoroughly with a stirrer to form a viscous coarse
138 dispersion. Six (6) mL of the resulting bubble-free dispersion was then dropped using a
139 pump-connected syringe into 60 mL of 10% w/v CaCl_2 solution kept under a gentle
140 agitation. Beads were allowed to stand in CaCl_2 solution for 30 min before being
141 collected and washed. Washing process involved soaking the freshly prepared beads in
142 deionized water with magnetic stirring at 300 rpm. Three washing protocols were
143 adopted; (i) beads were washed for a minute in 60 mL deionised water and the number of
144 washes was increased from 0 to 8 times. Formulations obtained by this protocol were
145 named according to the number of washings (N1, N2, N3, N4, N5, N6, N7 and N8). In
146 the second protocol, (ii) beads were washed one time in 60 mL deionised water for 1, 4 or
147 8 minutes. In the third, (iii) beads were washed one time for one minute in 60, 120 or 180

148 mL deionised water. All collected beads were finally dried in an air convection type oven
149 (Memmert, Germany) at a temperature of 40°C for 48h (Khoder, Tsapis, Domergue-
150 Dupont, Gueutin & Fattal, 2010, Sriamornsak & Kennedy, 2006).

151

152 2.3. *Weight uniformity testing*

153 To determine beads average weight, 20 beads were randomly sampled and accurately
154 weighed using Precisa scale 320 XB balance (220A, Switzerland). The results were
155 expressed as mean values \pm standard deviation of 20 determinations.

156

157 2.4. *Encapsulation efficiency (EE)*

158 Five beads were placed in a beaker containing 100 mL of the SIFm for 48h to allow their
159 complete dissolution. Samples were then taken, filtered and the amount of released IBU
160 was analysed by UV spectroscopy (SP-3000 Plus, Optima, Japan) at 264 nm. The EE was
161 determined according to the formula:

$$162 \quad EE = \frac{Mm}{Mi} \times 100$$

163 where Mm is the amount of drug measured in five dried beads and Mi is the initial
164 amount of drug dispersed in the alginate solution required to form five beads.

165

166 2.5. *Scanning electron microscopy*

167 Scanning electron microscopy (SEM) images of the typical external structure of the dried
168 beads N1 before and after their incubation for 2h in either SIFm or SIFp were obtained
169 using FEI Quanta 200 microscope (FEI company, Hillsboro, OR, USA) operated at an
170 accelerating voltage of 30 kV under low-vacuum mode.

171

172 2.6. *Fourier transform infrared analysis*

173 Fourier Transform Infrared (FT-IR) measurements of SA, IBU and IBU-loaded CABs
174 were performed using an FT-IR spectrometer (Thermo Scientific Nicolet 128 is5, Thermo
175 fisher, Madison, USA). The spectra were acquired over the wavenumber range of 4000 to
176 500 cm^{-1} at ambient temperature.

177

178 2.7. *X-ray diffraction*

179 The precipitate created during the swelling and dissolution studies in SIFp was collected,
180 washed three times with deionized water and dried at 105°C for 5h. The precipitate was
181 then examined by X-ray diffraction through Bruker SMART CCD area-detector
182 diffractometer (Bruker AXS, Germany).

183

184 2.8. Determination of Ca⁺² content

185 To determine the total amount of Ca⁺² retained by beads, five beads were weighed and
186 placed in a beaker containing 100 mL of SIFm. After 48h, samples were taken and the
187 amount of Ca⁺² was determined by the complexometric titration method using EDTA
188 solution and eriochrome black-T indicator (Lindstrom & Diehl, 1960). The same method
189 was adopted to determine the release kinetics of Ca⁺² from CABs N1 and N7 in SIFm.
190 The amount of released Ca⁺² was determined at time intervals of (5, 10, 15, 30, 60 and
191 120 min).

192

193 2.9. Beads swelling and drug release studies

194 Swelling and release studies were carried out on the CABs N1 and N7 in both SIFm and
195 SIFp using a USP rotating basket apparatus (ERWEKA DT 600 HH, Germany) at 100
196 rpm and 37°C. In each experiment, 40 beads were weighed and placed in the apparatus
197 vessel containing 400 mL of the swelling or the dissolution medium. For the swelling
198 study, beads were carefully taken out at time intervals, drained with filter paper to
199 remove excess water and weighted. Weight changes were calculated using the following
200 equation:

$$201 \quad \% \text{ weight change} = \frac{W_t - W_d}{W_d} \times 100$$

202 Where W_t is the weight of beads at a tested time and W_d is the weight of dry beads.

203 In a separate experiment, samples of tested medium were withdrawn at the same time
204 intervals, filtered and the released amount of IBU was determined by UV spectroscopy
205 (SP-3000 Plus, Optima) at 264 nm.

206

207 2.10. Mucoadhesion testing

208 The mucoadhesiveness of the CABs N1 and N7 in the SIFm were evaluated by *in vitro*

209 wash-off method (Lehr, Bouwstra, Schacht & Junginger, 1992, Prajapati, Tripathi,
210 Ubaidulla & Anand, 2008). Briefly, freshly excised pieces of sheep intestinal mucosa (2
211 cm × 2 cm) collected from a slaughter house were mounted on glass slides (7.5 × 2.5 cm)
212 using thread. 25 beads were spread onto each wet piece of mucosa and immediately hung
213 onto the arm of a USP tablet disintegration tester. The tissue specimens were given
214 regular up and down movements in a vessel containing 900 mL of SIFm kept at 37°C. At
215 hourly intervals up to 4 hours, the machine was stopped and the number of beads still
216 adhering onto the tissue was counted. Percent mucoadhesion was given by the following
217 formula.

218 $\% \text{ adhesive strength} = (\text{no. of beads remains} / \text{no. of applied microspheres}) \times 100$

219 *2.11. Statistical analysis*

220 Statistical significance was measured using the one-way analysis of variance (ANOVA)
221 and student's *t-tests* as appropriate. All values were expressed as the mean ± standard
222 deviation. Values of $P < 0.05$ were regarded as significantly different.


223

224

225 **3. Results and discussion**226 *3.1. Preparation of CABs*

227 IBU-loaded CABs were prepared by ionotropic gelation method. All formulations were
228 allowed to develop the same extent of cross-linking by fixing the polymer/drug ratio at
229 (3:2), the concentration of CaCl₂ solution at (10% w/v) and the cross-linking time at (30
230 min). According to Sriamornsak et al (2008), 20 minutes is the minimum time needed for
231 complete beads formation by ionotropic gelation. The concentration of CaCl₂ solution
232 used in this study (10% w/v ~ 0.9 M) is considerably higher than the minimum
233 concentration of counter ions needed to form beads which is in the low millimolar range
234 (Chuehet al., 2010). This high concentration of cross-linker solution was used in order to
235 allow a high degree of cross-linking as well as high entrapment of NCL-Ca. Before the
236 drying step, the fresh beads were washed using different washing protocols;
237 hypothetically, varying washing protocols might remove different amounts of NCL-Ca
238 from the beads whereas CL-Ca is not removable by washing processes (Bourgeois,
239 Gernet, Pradeau, Andremont & Fattal, 2006, Khoder, Tsapis, Huguet, Besnard, Gueutin
240 & Fattal, 2009). Therefore, the obtained beads should have the same extent of cross-
241 linking but different amount of NCL-Ca.

242 Obtained beads were spherical and homogenous regardless of the washing method (Fig.
243 1a). Scanning electron micrographs of CABs N1 showed relatively rough surfaces with
244 few small crystals probably due to partially crystallized IBU formed during the drying
245 step (Fig. 1b). This hypothesis is supported by ~~the high encapsulation efficiency (93.3%)~~
246 ~~(Fig. 4a) and by the disappearance of these crystals after 2 h of incubation in the SIFm~~
247 ~~(Fig. 1c); corresponding to the release of 30% of the loaded IBU (Fig. 5d).~~



248


249 **Fig.1.** SEM images of (a) dried IBU-loaded CABs N1 (scale bar = 1 mm), (b) the surface
 250 of IBU-loaded CABs N1 (scale bar = 500 μm), (c) the surface IBU-loaded CABs N1
 251 after 2 h of incubation in SIFm (scale bar = 400 μm) and (d) the surface IBU-loaded
 252 CABs N1 after 2 h of incubation in SIFp (scale bar = 200 μm). ~~X-ray diffractogram of
 253 the precipitates formed on the surface of CABs N1 in the SIFp.~~

254

255 3.2. FTIR spectroscopy

256 Fig. 2 shows the FTIR spectra of SA, IBU and IBU-loaded CABs N1. FTIR spectrum of
 257 SA shows a wide absorption bands at 3255 cm^{-1} indicating the stretching of O–H and
 258 sharp absorption bands at 1595 , 1405 and 1025 cm^{-1} representing COO^- (asymmetric),
 259 COO^- (symmetric) and C–O–C, respectively (Fig. 2A). FTIR spectrum of IBU
 260 demonstrates characteristic peaks at 1708 cm^{-1} and 2920 cm^{-1} (Fig. 2B), representing the
 261 carbonyl and hydroxyl stretching respectively. Similar IR spectra of SA and IBU have
 262 been previously reported in the literature (Jabeen, Chat, Maswal, Ashraf, Rather & Dar,
 263 2015, Setty, Sahoo & Sa, 2005, Velascoet al., 2011). IBU-loaded CAB spectrum shows
 264 almost the same characteristic bands observed in the spectrum of free IBU (Fig. 2C).
 265 These results confirm that the IBU did not undergo any chemical reaction during the
 266 beads preparation. Additionally, the absorption region of stretching vibrations of O–H

267 bonds of alginate in CABs appeared narrower and smaller than that of SA (Fig. 2C and
 268 2A). Daemi and Barikani (2012) observed a similar difference in calcium alginate
 269 nanoparticles. They attributed this difference to the participation of hydroxyl and
 270 carboxylate groups of alginate with Ca^{+2} in the formation of egg-box structure and a
 271 consequent decrease in hydrogen bonding between hydroxyl functional groups; this
 272 affords a narrow O–H stretching band in calcium alginate (Daemi & Barikani, 2012).
 273 Similarly, the intensity of alginate peaks corresponding to COO^- (asymmetric and
 274 symmetric) and C–O–C decreased significantly after their crosslinking with Ca^{+2} . This
 275 might be attributed to the low percentage ion-bonding of Ca^{+2} relative to Na^+
 276 (Papageorgiou, Katsaros, Kouvelos, Nolan, Le Deit & Kanellopoulos, 2006).




277
 278 **Fig. 2.** FTIR spectra of (A) SA, (B) IBU, and (C) IBU-loaded CABs N1.

279

280 3.3. Determination of the amount of Ca^{+2} retained by beads

281 Fig. 3 shows that increasing the number and the duration of washes had a significant
 282 influence on beads Ca^{+2} content (Fig. 3a and 3b). However, the impact of increasing the
 283 volume of washes was less significant (Fig. 3c). Interestingly, increasing the number of
 284 washes was able to remove an additional amount of Ca^{+2} until the sixth wash ($P < 0.05$).
 285 Afterward, washing had no significant impact on the amount of Ca^{+2} (Fig. 3a). This
 286 finding is in agreement with the other research findings reported in literature (Bourgeois,

287 Gernet, Pradeau, Andreumont & Fattal, 2006, Khoder, Tsapis, Domergue-Dupont, Gueutin
 288 & Fattal, 2010, Khoder, Tsapis, Hugué, Besnard, Gueutin & Fattal, 2009). This result
 289 indicates that the Ca^{+2} remained within the beads after the sixth wash was already cross-
 290 linked, i.e. non-washable CL-Ca. Accordingly, approximately 70% of the initial Ca^{+2}
 291 content is NCL-Ca and less than 30% is CL-Ca, i.e. all Ca^{+2} retained in beads N7, N6
 292 and N8 (Fig. 3a). To confirm these results, the release kinetic of Ca^{+2} from beads was
 293 also studied (Fig. 3d and 3e). According to Kikuchi et al and others, Ca^{+2} release from
 294 CABs was bimodal; NCL-Ca is firstly released followed by the release of CL-Ca
 295 (Alvarez-Lorenzo, Blanco-Fernandez, Puga & Concheiro, 2013, Kikuchi, Kawabuchi,
 296 Watanabe, Sugihara, Sakurai & Okano, 1999). Similarly, Fig. 3 shows that Ca^{+2} release
 297 from CABs N1 was bimodal with the first phase releasing approximately 75% of total
 298 Ca^{+2} (Fig. 3d). On the other hand, the release profile of Ca^{+2} from CABs N7 was
 299 monomodal (Fig. 3e), which is expected according to Fig. 4a as all Ca^{+2} remained in the
 300 beads N7 are cross-linked.




301

302 **Fig. 3.** Ca^{+2} content in CABs (mg Ca / bead) as a function of (a) number, (b) duration and
 303 (c) volume of washes ($n=3 \pm \text{SD}$). Figures (d) and (e) represent the cumulative release of
 304 Ca^{+2} plotted against the square root of time from CABs N1 in SIFm and in SIFm
 305 respectively ($n=3 \pm \text{SD}$).

306

307 *3.4. Encapsulation efficiency (EE)*

308 The EE is significantly affected by the washing process (Fig. 4a and 4b). As washing
 309 increases in term of number and duration, an additional and significant amount ($p < 0.05$)
 310 of loaded drug is removed from the beads. Since the loaded drug did not undergo any
 311 chemical covalent linking inside the beads (IR results), the amount of encapsulated IBU
 312 was descending during the 8 washes. Similar findings were reported relating to the effect
 313 of beads curing time in the gelation medium on the drug EE. On the other hand, the
 314 impact of the washing volume on the EE was less significant ($p > 0.05$) (data not shown);
 315 this is probably due to the sink conditions being attained with the smallest volume of
 316 washing (i.e. 60 mL).



317

318 **Fig. 4.** Encapsulation efficiency of IBU in CABs as a function of (a) number and (b)
 319 duration of washes ($n=3 \pm SD$). Figures (c) and (d) represent the average weight of dry
 320 CABs as a function of number and duration of washes respectively ($n=3 \pm SD$).

321

322 *3.5. Impact of the NCL-Ca on the weights of dry beads*

323 The washing process and the amount of NCL-Ca retained by beads have a significant
 324 impact on the weight of dry CABs. As shown in Fig. 4, beads weight decreased


325 significantly as the number and the duration of washes increased ($P < 0.05$) (Fig. 4c and
326 4d). In contrast, increasing the volume of washes had a less significant effect on beads
327 weight especially when the volume of washing exceeded 120 mL (data not shown).
328 Interestingly, the changes in beads weight were consistent with Ca^{+2} content results; this
329 might be explained by the hygroscopic properties of the Ca^{+2} which led to the
330 corresponding increases in the water contents of the beads.

331

332 3.6. Impact of NCL-Ca on the beads swelling in SIFs

333 Fig. 5 shows the swelling profile of the beads N1 and N7 in the SIFp (Fig. 5a) and SIFm
334 (Fig. 5b). In both media, CABs N7 swelled more than CABs N1. However, each bead
335 showed dissimilar swelling profiles in both media. For example, beads N7 swelled twice
336 as much in the SIFp (3800% after 240 min) compared with the SIFm (1915% after 240
337 min). In contrast, the swelling extent of CABs N1 was significantly lower in the SIFp
338 than that in the SIFm. Swelling process lasted 6 h for SIFm and 4 h for SIFp after which
339 the beads started to lose their integrity and overall weight. Accordingly, SEM shows a
340 formation of condense layer of crystals on the surface of CABs N1 (dried after incubation
341 of 2 h in SIFp) (Fig. 1d), whereas no crystals were observed after incubating the same
342 beads for the same time in the SIFm (Fig. 1c). Comparable swelling behaviors of calcium
343 polysaccharide gels in different SIFs were previously reported elsewhere (Assifaoui,
344 Chambin & Cayot, 2011, Sriamornsak & Kennedy, 2008). Apparently, when CABs are
345 placed in a medium containing monovalent electrolytes, e.g. SIFs, Ca^{+2} are exchanged
346 with monovalent ions (Khoder, Tsapis, Huguet, Besnard, Gueutin & Fattal, 2009, Kim,
347 Chung, Shin, Yam & Chung, 2008). Therefore, when the beads contain only CL-Ca, e.g.
348 beads N7, cross-linker ions are removed and beads swell rapidly. However, in case of N1,
349 NCL-Ca replenishes CL-Ca during the initial stages of ions exchanging with monovalent
350 cations, hence, protects the egg-box structure and decelerates swelling. Phosphate salts
351 play the role of chelating agent and promotes Ca^{+2} extraction from beads (Lee & Min,
352 1996). However, extracted Ca^{+2} could react with phosphate ions and precipitate on beads
353 surface (Assifaoui, Chambin & Cayot, 2011). Accordingly, Ca^{+2} content of CABs N1
354 were high enough to generate a condense layer of calcium phosphate precipitated on
355 beads surface as shown by the SEM results (Fig. 1d). This layer plays a protective role

356 preventing the beads from further swelling. On the other hand, CABs N7, containing a
 357 limited amount of Ca^{+2} , swelled then disintegrated as no the protective layer of calcium
 358 phosphate were formed on the beads surface. This is confirmed by X-ray diffraction
 359 analysis of the precipitate formed on the surface of CABs N1 during the incubation in
 360 SIFp (Fig. 1 supplementary information) as all the principal peaks identified on the
 361 precipitate XRD pattern were identical to those of dicalcium phosphate (the monetite -
 362 CaHPO_4) (Tas, 2009).



363
 364 **Fig. 5.** Figures (a) and (b) represent the swelling profiles of CABs N1 and N7 in SIFp
 365 and SIFm respectively ($n=3 \pm \text{SD}$). Figures (c) and (d) represent IBU release profiles
 366 from CABs N1 and CABs N7 in SIFp and SIFm respectively ($n=3 \pm \text{SD}$).

367

368 3.7. Impact of NCL-Ca on the drug release in SIFs


369 Fig. 5 shows the cumulative release of IBU from CABs N1 and N7 in both SIFm (Fig.
 370 5c) and SIFm (Fig. 5d). IBU release from CABs N1 in the SIFm was significantly faster
 371 than that from CABs N7 (Fig. 5d). However, there were no significant differences

372 between the drug release profiles of both CABs N1 and N7 in SIFp during the first 3
373 hours of the dissolution test ($P > 0.05$) (Fig. 5c). Thereafter, drug release profile of CABs
374 N7 became significantly faster than that of CABs N1 ($P < 0.05$) (Fig. 5c). Drug release
375 from CABs is mainly controlled by swelling and/or drug diffusion through the swollen
376 polysaccharide matrix (Siepmann & Siepmann, 2012). Beads degradation may also
377 hasten drug release rate, particularly in late stages of the release. Swollen Alginate beads
378 possess pores with approximately 5 to 200 nm diameters, which is definitely larger than
379 the dimension of IBU molecules ($0.5 \times 1.2 \times 0.8$ nm) (Hillerstrom, van Stam &
380 Andersson, 2009, Inger-Lill, Olav, Olav, Kjetill & Per Chr, 1977, Otterlei, Ostgaard,
381 Skjak-Braek, Smidsrod, Soon-Shiong & Espevik, 1991, Tanaka, Matsumura & Veliky,
382 1984). Therefore, the release of IBU through alginate beads might not be controlled by
383 diffusion rather than the rate of swelling process; thus, the degradation of beads. Beads
384 swelling increases the diffusion pathway and this reduces the drug-concentration gradient
385 and decreases the drug-release rate (Siepmann & Siepmann, 2012). In correspondence to
386 bead swelling results (Fig. 5a and 5b), IBU release in SIFm from CABs N7 was slower
387 than that of CABs N1 the least swollen bead (Fig. 5d). In contrast, using SIFp, IBU
388 release from beads N7 increased dramatically after 3 h (Fig. 5c), the beginning of beads
389 disintegration (Fig. 5a). Therefore, IBU release from CABs N7 in SIFp is suggested to be
390 predominantly governed the erosion and disintegration of these beads after 3 h of
391 incubation. On the other hand, the protective layer of the dicalcium phosphate precipitate
392 formed on the surface of the CABs N1 slows down the drug release in SIFp during the
393 same period of time. These results highlight the importance of the composition of SIFs
394 for drug release studies. Phosphate buffer is mainly used in the SIFs thanks to its high
395 buffering capacity. However, phosphate buffer is not bio-relevant and do not simulate the
396 composition and the ionic strength of biological fluids (Alhnan, Kidia & Basit, 2011,
397 Fadda, Merchant, Arafat & Basit, 2009). Therefore, and in correspondence with our
398 results, alternative buffers, such as bicarbonate, maleate or acetate buffer, have been
399 suggested for dissolution studies (Alhnan, Kidia & Basit, 2011, Boni, Brickl &
400 Dressman, 2007, Fadda, Merchant, Arafat & Basit, 2009).

401

402 *3.8. Impact of NCL-Ca on CABs mucoadhesiveness in SIFm*

403 Fig. 6 shows the wash-off behaviour of CABs N1 and N7 performed in SIFm. The results
 404 show the percent of beads remained adhering to the intestine per time (min). The
 405 mucoadhesiveness was significantly different for both CABs. CABs N7 display a higher
 406 mucoadhesiveness with $48 \pm 6.9\%$ of beads remained adherent on the mucosal tissue after
 407 2 h of the wash-off test. Comparable mucoadhesion properties of CABs were previously
 408 reported in the literature (Adebisi, Laity & Conway, 2015, Veerareddy, Tedla, Banda,
 409 Bandari & Jukanti, 2011). On the other hand, only $6.6 \pm 4.6\%$ of CABs N1 were still
 410 adhered on the mucosal tissue after the same period (Fig. 6).



411

412 **Fig.6.** Mucoadhesion of CABs N1 and CABs N7 in SIFm ($n=3 \pm SD$).

413 The mucoadhesiveness of alginate is mainly related to the ability of carboxylic groups to
 414 form hydrogen-bonds with oligosaccharide chains of mucins (Khutoryanskiy, 2011).
 415 Indeed, the difference in the mucoadhesion behaviour of CABs N1 and N7 might be
 416 explained by the difference in the Ca^{+2} contents of these two formulations (Fig. 3a). It is
 417 well known that Ca^{+2} decreases the viscosity of mucus and may collapse entirely the
 418 mucin gel (Forstner & Forstner, 1976, Lai, Wang, Wirtz & Hanes, 2009, Raynal,
 419 Hardingham, Sheehan & Thornton, 2003). Decreasing the mucus viscosity would have a
 420 direct and negative impact on the mucoadhesion properties of CABs as the mucus layer
 421 with lower viscosity promotes weaker retention ability and less available groups for
 422 interactions with alginate.

423

424

425

426

427

428

429

430

431

432

433 4. Conclusion

434 In this study, IBU-loaded CABs with the same degree of crosslinking and different
435 amounts of NCL-Ca were prepared in order to investigate the influence of NCL-Ca on
436 beads properties and the drug release profiles in SIFs. This study showed that the
437 washing step, often neglected by researchers, had a significant impact on the amount
438 NCL-Ca retained by CABs. The washing process in term of number or duration
439 significantly influenced the amount of NCL-Ca retained by beads; hence the beads
440 properties such as EE, mucoadhesiveness, swelling and drug release in SIFs. These
441 results highlight the importance of washing step and the amount of NCL-Ca when
442 developing calcium alginate-based drug delivery systems. This study showed also that the
443 composition of the SIFs is of great significance in order to perform reliable and consistent
444 swelling and release studies.

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460 **References**

- 461 A. O. Adebisi, P. R. Laity, & B. R. Conway. (2015). Formulation and evaluation of
462 floating mucoadhesive alginate beads for targeting *Helicobacter pylori*. *Journal of*
463 *Pharmacy and Pharmacology*, 67(4), 511-524.
- 464 M. A. Alhnan, E. Kidia, & A. W. Basit. (2011). Spray-drying enteric polymers from
465 aqueous solutions: a novel, economic, and environmentally friendly approach to produce
466 pH-responsive microparticles. *Eur J Pharm Biopharm*, 79(2), 432-439.
- 467 S. Alipour, H. Montaseri, & M. Tafaghodi. (2010). Preparation and characterization of
468 biodegradable paclitaxel loaded alginate microparticles for pulmonary delivery. *Colloids*
469 *and Surfaces B: Biointerfaces*, 81(2), 521-529.
- 470 C. Alvarez-Lorenzo, B. Blanco-Fernandez, A. M. Puga, & A. Concheiro. (2013).
471 Crosslinked ionic polysaccharides for stimuli-sensitive drug delivery. *Adv Drug Deliv*
472 *Rev*, 65(9), 1148-1171.
- 473 A. Assifaoui, O. Chambin, & P. Cayot. (2011). Drug release from calcium and zinc
474 pectinate beads: Impact of dissolution medium composition. *Carbohydrate Polymers*,
475 85(2), 388-393.
- 476 S. Azarnia, B. H. Lee, N. Robert, & C. P. Champagne. (2008). Microencapsulation of a
477 recombinant aminopeptidase (PepN) from *Lactobacillus rhamnosus* S93 in chitosan-
478 coated alginate beads. *J Microencapsul*, 25(1), 46-58.
- 479 M. Barzegar-Jalali, J. Hanaee, Y. Omid, S. Ghanbarzadeh, S. Ziaee, R. Bairami-
480 Atashgah, & K. Adibkia. (2013). Preparation and evaluation of sustained release calcium
481 alginate beads and matrix tablets of acetazolamide. *Drug Res (Stuttg)*, 63(2), 60-64.

- 482 J. E. Boni, R. S. Brickl, &J. Dressman. (2007). Is bicarbonate buffer suitable as a
483 dissolution medium? *J Pharm Pharmacol*, 59(10), 1375-1382.
- 484 S. Bourgeois, M. Gernet, D. Pradeau, A. Andreumont, &E. Fattal. (2006). Evaluation of
485 critical formulation parameters influencing the bioactivity of beta-lactamases entrapped
486 in pectin beads. *International Journal of Pharmaceutics*, 324(1), 2-9.
- 487 B. H. Chueh, Y. Zheng, Y. S. Torisawa, A. Y. Hsiao, C. Ge, S. Hsiong, N. Huebsch, R.
488 Franceschi, D. J. Mooney, &S. Takayama. (2010). Patterning alginate hydrogels using
489 light-directed release of caged calcium in a microfluidic device. *Biomed Microdevices*,
490 12(1), 145-151.
- 491 H. Daemi, &M. Barikani. (2012). Synthesis and characterization of calcium alginate
492 nanoparticles, sodium homopolymannuronate salt and its calcium nanoparticles. *Scientia*
493 *Iranica*, 19(6), 2023-2028.
- 494 F. Despang, A. Bernhardt, A. Lode, R. Dittrich, T. Hanke, S. J. Shenoy, S. Mani, A.
495 John, &M. Gelinsky. (2013). Synthesis and physicochemical, in vitro and in vivo
496 evaluation of an anisotropic, nanocrystalline hydroxyapatite bisque scaffold with parallel-
497 aligned pores mimicking the microstructure of cortical bone. *Journal of Tissue*
498 *Engineering and Regenerative Medicine*, n/a-n/a.
- 499 I. Donati, S. Holtan, Y. A. Morch, M. Borgogna, M. Dentini, &G. Skjak-Braek. (2005).
500 New hypothesis on the role of alternating sequences in calcium-alginate gels.
501 *Biomacromolecules*, 6(2), 1031-1040.
- 502 H. M. Fadda, H. A. Merchant, B. T. Arafat, &A. W. Basit. (2009). Physiological
503 bicarbonate buffers: stabilisation and use as dissolution media for modified release
504 systems. *Int J Pharm*, 382(1-2), 56-60.

- 505 M. Fathy, S. M. Safwat, S. M. el-Shanawany, S. Shawky Tous, &M. Otagiri. (1998).
506 Preparation and evaluation of beads made of different calcium alginate compositions for
507 oral sustained release of tiaramide. *Pharm Dev Technol*, 3(3), 355-364.
- 508 J. F. Forstner, &G. G. Forstner. (1976). Effects of Calcium on Intestinal Mucin:
509 Implications for Cystic Fibrosis. *Pediatr Res*, 10(6), 609-613.
- 510 M. George, &T. E. Abraham. (2006). Polyionic hydrocolloids for the intestinal delivery
511 of protein drugs: alginate and chitosan--a review. *J Control Release*, 114(1), 1-14.
- 512 T. K. Giri, D. Thakur, A. Alexander, Ajazuddin, H. Badwaik, &D. K. Tripathi. (2012).
513 Alginate based hydrogel as a potential biopolymeric carrier for drug delivery and cell
514 delivery systems: present status and applications. *Curr Drug Deliv*, 9(6), 539-555.
- 515 C. J. Gray, &J. Dowsett. (1988). Retention of insulin in alginate gel beads. *Biotechnol*
516 *Bioeng*, 31(6), 607-612.
- 517 P. W. Heng, L. W. Chan, &T. W. Wong. (2003). Formation of alginate microspheres
518 produced using emulsification technique. *J Microencapsul*, 20(3), 401-413.
- 519 A. Hillerstrom, J. van Stam, &M. Andersson. (2009). Ibuprofen loading into
520 mesostructured silica using liquid carbon dioxide as a solvent. *Green Chemistry*, 11(5),
521 662-667.
- 522 A. Inger-Lill, S. Olav, S. D. Olav, O. Kjetill, &H. Per Chr. (1977). Some Biological
523 Functions of Matrix Components in Benthic Algae in Relation to Their Chemistry and
524 the Composition of Seawater. *Cellulose Chemistry and Technology* (Vol. 48, pp. 361-
525 381): AMERICAN CHEMICAL SOCIETY.
- 526 C. Iskenderoglu, F. Acarturk, D. Erdogan, &Y. Bardakci. (2013). In vitro and in vivo
527 investigation of low molecular weight heparin-alginate beads for oral administration. *J*
528 *Drug Target*, 21(4), 389-406.

- 529 S. Jabeen, O. A. Chat, M. Maswal, U. Ashraf, G. M. Rather, &A. A. Dar. (2015).
530 Hydrogels of sodium alginate in cationic surfactants: Surfactant dependent modulation of
531 encapsulation/release toward Ibuprofen. *Carbohydrate Polymers*, 133, 144-153.
- 532 E. Jamstorp, A. Bodin, P. Gatenholm, A. Jeppsson, &M. Stromme. (2010). Release of
533 antithrombotic drugs from alginate gel beads. *Curr Drug Deliv*, 7(4), 297-302.
- 534 M. Khoder, N. Tsapis, V. Domergue-Dupont, C. Gueutin, &E. Fattal. (2010). Removal of
535 residual colonic ciprofloxacin in the rat by activated charcoal entrapped within zinc-
536 pectinate beads. *Eur J Pharm Sci*, 41(2), 281-288.
- 537 M. Khoder, N. Tsapis, H. Huguet, M. Besnard, C. Gueutin, &E. Fattal. (2009). Removal
538 of ciprofloxacin in simulated digestive media by activated charcoal entrapped within
539 zinc-pectinate beads. *Int J Pharm*, 379(2), 251-259.
- 540 V. V. Khutoryanskiy. (2011). Advances in mucoadhesion and mucoadhesive polymers.
541 *Macromol Biosci*, 11(6), 748-764.
- 542 A. Kikuchi, M. Kawabuchi, A. Watanabe, M. Sugihara, Y. Sakurai, &T. Okano. (1999).
543 Effect of Ca²⁺-alginate gel dissolution on release of dextran with different molecular
544 weights. *J Control Release*, 58(1), 21-28.
- 545 W.-T. Kim, H. Chung, I.-S. Shin, K. L. Yam, &D. Chung. (2008). Characterization of
546 calcium alginate and chitosan-treated calcium alginate gel beads entrapping allyl
547 isothiocyanate. *Carbohydrate Polymers*, 71(4), 566-573.
- 548 S. K. Lai, Y. Y. Wang, D. Wirtz, &J. Hanes. (2009). Micro- and macrorheology of
549 mucus. *Adv Drug Deliv Rev*, 61(2), 86-100.
- 550 B.-J. Lee, &G.-H. Min. (1996). Oral controlled release of melatonin using polymer-
551 reinforced and coated alginate beads. *International Journal of Pharmaceutics*, 144(1),
552 37-46.

- 553 C.-M. Lehr, J. A. Bouwstra, E. H. Schacht, &H. E. Junginger. (1992). In vitro evaluation
554 of mucoadhesive properties of chitosan and some other natural polymers. *International*
555 *Journal of Pharmaceutics*, 78(1), 43-48.
- 556 F. Lindstrom, &H. Diehl. (1960). Indicator for the Titration of Calcium Plus Magnesium
557 with (Ethylenedinitrilo)tetraacetate. *Analytical Chemistry*, 32(9), 1123-1127.
- 558 Y. A. Morch, I. Donati, B. L. Strand, &G. Skjak-Braek. (2006). Effect of Ca²⁺, Ba²⁺,
559 and Sr²⁺ on alginate microbeads. *Biomacromolecules*, 7(5), 1471-1480.
- 560 M. Otterlei, K. Ostgaard, G. Skjak-Braek, O. Smidsrod, P. Soon-Shiong, &T. Espevik.
561 (1991). Induction of cytokine production from human monocytes stimulated with
562 alginate. *J Immunother* (1991), 10(4), 286-291.
- 563 S. K. Papageorgiou, F. K. Katsaros, E. P. Kouvelos, J. W. Nolan, H. Le Deit, &N. K.
564 Kanellopoulos. (2006). Heavy metal sorption by calcium alginate beads from *Laminaria*
565 *digitata*. *Journal of Hazardous Materials*, 137(3), 1765-1772.
- 566 S. K. Prajapati, P. Tripathi, U. Ubaidulla, &V. Anand. (2008). Design and Development
567 of Gliclazide Mucoadhesive Microcapsules: In Vitro and In Vivo Evaluation. *AAPS*
568 *PharmSciTech*, 9(1), 224-230.
- 569 P. S. Rajinikanth, C. Sankar, &B. Mishra. (2003). Sodium alginate microspheres of
570 metoprolol tartrate for intranasal systemic delivery: development and evaluation. *Drug*
571 *Deliv*, 10(1), 21-28.
- 572 B. D. Raynal, T. E. Hardingham, J. K. Sheehan, &D. J. Thornton. (2003). Calcium-
573 dependent protein interactions in MUC5B provide reversible cross-links in salivary
574 mucus. *J Biol Chem*, 278(31), 28703-28710.

- 575 K. Schutz, F. Despang, A. Lode, &M. Gelinsky. (2014). Cell-laden biphasic scaffolds
576 with anisotropic structure for the regeneration of osteochondral tissue. *J Tissue Eng*
577 *Regen Med*.
- 578 C. M. Setty, S. S. Sahoo, &B. Sa. (2005). Alginate-coated alginate-polyethyleneimine
579 beads for prolonged release of furosemide in simulated intestinal fluid. *Drug Dev Ind*
580 *Pharm*, 31(4-5), 435-446.
- 581 J. Siepmann, &F. Siepmann. (2012). Swelling Controlled Drug Delivery Systems. In J.
582 Siepmann, R. A. Siegel & M. J. Rathbone (Eds.). *Fundamentals and Applications of*
583 *Controlled Release Drug Delivery* (pp. 153-170): Springer US.
- 584 P. K. Singh, P. K. Deol, &I. P. Kaur. (2012). Entrapment of *Lactobacillus acidophilus*
585 into alginate beads for the effective treatment of cold restraint stress induced gastric
586 ulcer. *Food Funct*, 3(1), 83-90.
- 587 A. Sosnik. (2014). Alginate Particles as Platform for Drug Delivery by the Oral Route:
588 State-of-the-Art. *ISRN Pharm*, 2014, 926157.
- 589 P. Sriamornsak, &R. A. Kennedy. (2006). Development of polysaccharide gel-coated
590 pellets for oral administration. 2. Calcium alginate. *Eur J Pharm Sci*, 29(2), 139-147.
- 591 P. Sriamornsak, &R. A. Kennedy. (2008). Swelling and diffusion studies of calcium
592 polysaccharide gels intended for film coating. *Int J Pharm*, 358(1-2), 205-213.
- 593 P. Sriamornsak, N. Thirawong, &K. Korkerd. (2007). Swelling, erosion and release
594 behavior of alginate-based matrix tablets. *Eur J Pharm Biopharm*, 66(3), 435-450.
- 595 H. Tanaka, M. Matsumura, &I. A. Veliky. (1984). Diffusion characteristics of substrates
596 in Ca-alginate gel beads. *Biotechnol Bioeng*, 26(1), 53-58.

- 597 A. C. Tas. (2009). Monetite (CaHPO₄) Synthesis in Ethanol at Room Temperature.
598 *Journal of the American Ceramic Society*, 92(12), 2907-2912.
- 599 K. Tateshita, S. Sugawara, T. Imai, &M. Otagiri. (1993). Preparation and evaluation of a
600 controlled-release formulation of nifedipine using alginate gel beads. *Biol Pharm Bull*,
601 16(4), 420-424.
- 602 H. H. Tonnesen, &J. Karlsten. (2002). Alginate in drug delivery systems. *Drug Dev Ind*
603 *Pharm*, 28(6), 621-630.
- 604 P. R. Veerareddy, S. Tedla, S. R. Banda, S. Bandari, &R. Jukanti. (2011). Preparation
605 and evaluation of mucoadhesive cefdinir microcapsules. *J Adv Pharm Technol Res*, 2(2),
606 115-120.
- 607 D. Velasco, C. B. Danoux, J. A. Redondo, C. Elvira, J. San Román, P. S. Wray, &S. G.
608 Kazarian. (2011). pH-sensitive polymer hydrogels derived from morpholine to prevent
609 the crystallization of ibuprofen. *Journal of Controlled Release*, 149(2), 140-145.
- 610 F. Xu, L. Xu, Q. Wang, Z. Ye, Y. Zhou, &W. S. Tan. (2014). 3D Dynamic Culture of
611 Rabbit Articular Chondrocytes Encapsulated in Alginate Gel Beads Using Spinner Flasks
612 for Cartilage Tissue Regeneration. *Biomed Res Int*, 2014, 539789.
- 613 Y.-T. Yang, A. J. Di Pasqua, W. He, T. Tsai, K. Sueda, Y. Zhang, &M. Jay. (2013).
614 Preparation of alginate beads containing a prodrug of diethylenetriaminepentaacetic acid.
615 *Carbohydrate Polymers*, 92(2), 1915-1920.

616

617

618

619

620

621

622 **Highlights**

- 623 • Calcium alginate beads with different amounts of Ca^{+2} were prepared.
- 624 • Beads washing resulted in removing non-cross-linked Ca^{+2} (NCL-Ca) only.
- 625 • Ca^{+2} release was bimodal; NCL-Ca was burst-released followed by CL-Ca
- 626 release.
- 627 • NCL-Ca had a significant impact on bead swelling and drug release in SIFs.
- 628 • NCL-Ca had a significant impact on the mucoadhesive properties of beads.

629

630

631


632

633

634

635

Supplementary Information



636

637 **Figure 1:** X-ray diffractogram of the precipitates formed on the surface of CABs N1 in the
638 SIFp.

639 All the principal peaks identified on the X-ray diffractogram of the precipitate formed on
640 the surface of CABs N1 in the SIFp are identical to those of dicalcium phosphate (the
641 monetite - CaHPO_4) (Tas, 2009).

642

643

644 References

645 A. C. Tas. (2009). Monetite (CaHPO_4) Synthesis in Ethanol at Room Temperature.646 *Journal of the American Ceramic Society*, 92(12), 2907-2912.

647

648

Accepted Manuscript